Page Loading...
Layout Table~~~~1736~1736~~
Emerging Markets for Microfluidic Applications~
Published by Yole Développement, May 2007

Microfluidics is becoming a key technology integrated in most of Life Science companies’ development roadmap. Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.~Published by Yole Développement, May 2007

Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.

The microfluidics market for research applications will steadily grow in the 5 coming years, but the double digit growth will come from the diagnostic market. Indeed microfluidics has a strong competitive advantage in this market enabling analysis automation and decentralisation, but also in facilitating the molecular diagnostic emergence and success.

Microfluidics components for diagnostic are expected to reach €1b market value in 2011 with a Total Accessible Market of about 5b€.

If microfluidics proof of concept is validated now, no real standard has been defined yet. Dedicated to research applications, microfluidics products are rather produced in low volume. The microfluidics penetration in the diagnostic market will require the technology validation from a manufacturability point of view. Only the technologies fitting with the diagnostic market cost and regulation pressure will success.

Such standardisation will lead to a structuration of the industrial food chain. New players are entering the field. Some microfluidics companies adapt their business model to the market evolution. Mergers and acquisitions are also increasing.

Most of diagnostic companies have positioned microfluidics in their development roadmap as a key technology to support their growth strategy.

Indeed microfluidics is clearly identified as an enabling technology to support the development of the point of care and the molecular biology markets.

All ingredients are gathered for success:

1 - Microfluidics is overcoming the proof of concept milestones. Some companies are today positioned in microfluidics industrialisation

2 - Microfluidics provides the expected technical solutions required in the diagnostic market evolution

3 - Innovative high tech companies are entering the diagnostic field. They will participate to the market dynamism in facilitating convergence of technologies like microfluidics and biomarkers.~Emerging Markets for Microfluidic Applications (Single User License)|1052|Emerging Markets for Microfluidic Applications (Corporate License)|1172|Emerging Markets for Microfluidic Applications (Corporate Multi Site License)|1173|~1736~3201~~
High-Content Analysis 2007~
Published by Select Biosciences, April 2007

This report presents an industry analysis of the High-Content Analysis Marketplace in both qualitative and quantitative terms. High-Content Analysis involves the use of instrumentation, reagents, and informatics to perform multi-parametric analysis of biological systems—ie., lots of different cellular parameters studied in parallel. High-Content Analysis is crucial in the biological characterization [fine-structure characterization] of lead compounds primarily in the drug discovery process. Select Biosciences’ industry tracking of this space involves analyses of the technology trends as well as market analysis of instrumentation and reagents that are utilized in High-Content Analysis. Select Biosciences presents primary market survey data in this report that describe important qualitative and quantitative metrics in the High-Content Analysis marketplace—these parameters describe the marketplace in detail.~Published by Select Biosciences, April 2007

This report presents an industry analysis of the High-Content Analysis Marketplace in both qualitative and quantitative terms. High-Content Analysis involves the use of instrumentation, reagents, and informatics to perform multi-parametric analysis of biological systems—ie., lots of different cellular parameters studied in parallel. High-Content Analysis is crucial in the biological characterization [fine-structure characterization] of lead compounds primarily in the drug discovery process. Select Biosciences’ industry tracking of this space involves analyses of the technology trends as well as market analysis of instrumentation and reagents that are utilized in High-Content Analysis. Select Biosciences presents primary market survey data in this report that describe important qualitative and quantitative metrics in the High-Content Analysis marketplace—these parameters describe the marketplace in detail.

Topics Covered in This Report

Table of Contents~High-Content Analysis 2007 (Single User Print License)|1003|High-Content Analysis 2007 (Electronic Site License)|1004|~1736~3136~~
Fluorescence Lifetime Trends 2007~
Published by HTStec, March 2007

This market report summarizes the results of HTStec’s global web-based benchmarking survey on FLT. Amongst other subjects, the survey investigated the following aspects of FLT-based measurements ; general perception; current level of awareness; current level of use; areas where FLT has been applied; awareness and feedback on commercial instruments; preference for the type of new FLT instrument; fluorescence readouts to be replaced with FLT; interest in commercially available FLT assays and lifetime dyes; most important features of a universal FLT kinase assay and interest in replacing current assays with a universal FLT kinase assay.~Published by HTStec, March 2007

This market report summarizes the results of HTStec’s global web-based benchmarking survey on FLT. Amongst other subjects, the survey investigated the following aspects of FLT-based measurements ; general perception; current level of awareness; current level of use; areas where FLT has been applied; awareness and feedback on commercial instruments; preference for the type of new FLT instrument; fluorescence readouts to be replaced with FLT; interest in commercially available FLT assays and lifetime dyes; most important features of a universal FLT kinase assay and interest in replacing current assays with a universal FLT kinase assay.

Table of Contents~Electronic Site License|1064|~1736~3251~~
Microplate Instrument Trends 2007~
Published by HTStec, January 2007

This market report summarizes the results of HTStec’s second industry wide global Pharma and Biotech web-based benchmarking survey on microplate instruments. The objective of the report was to comprehensively document current preferences and satisfaction with microplate instrumentation as well as future needs and requirements. The survey looked at instrument preference, satisfaction and requirements in 2007 and future predictions (2008). Amongst the subjects investigated were factors that currently limit ability to be more productive; level of awareness and interest in adopting QA, audit and tracking related tools; detection liquid handling and sample preparation, plate washing and plate stacking instruments used today; future purchase plans and preferred vendors; interest in accessing microplate imaging applications; factors affecting instrument purchasing decisions including new applications; unmet needs that exist in in microplate instrumentation today.~Published by HTStec, January 2007

This market report summarizes the results of HTStec’s second industry wide global Pharma and Biotech web-based benchmarking survey on microplate instruments. The objective of the report was to comprehensively document current preferences and satisfaction with microplate instrumentation as well as future needs and requirements. The survey looked at instrument preference, satisfaction and requirements in 2007 and future predictions (2008). Amongst the subjects investigated were factors that currently limit ability to be more productive; level of awareness and interest in adopting QA, audit and tracking related tools; detection liquid handling and sample preparation, plate washing and plate stacking instruments used today; future purchase plans and preferred vendors; interest in accessing microplate imaging applications; factors affecting instrument purchasing decisions including new applications; unmet needs that exist in in microplate instrumentation today.

Table of Contents~Electronic Site License|1065|~1736~3253~~
Kinase Screening Profiling Trends 2006~
Published by HTStec, September 2006

This market report summarizes the results of the second industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling. The objective of this study was to document current practices and preferences and to understand future user requirements (particularly in respect of the need for outsourced services) in kinase screening and profiling.

The survey looked at various points including in-house and outsourced kinase screening and profiling as practiced in 2006 and predicted for 2007 and 2008. The following specific areas were investigated : therapeutic areas using kinase assays, kinase panel profiling approach; preferred assay technology, supplier and outsourced fee-for-service providers; kinase profiling budgets and breakdown; interest in label free assays, multiplexed methods of kinase profiling and cell-based approaches for signaling pathway analysis of kinase inhibitors and features of a new kinase platform of greatest interest to respondents.~
Published by HTStec, September 2006

This market report summarizes the results of the second industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling. The objective of this study was to document current practices and preferences and to understand future user requirements (particularly in respect of the need for outsourced services) in kinase screening and profiling.

The survey looked at various points including in-house and outsourced kinase screening and profiling as practiced in 2006 and predicted for 2007 and 2008. The following specific areas were investigated : therapeutic areas using kinase assays, kinase panel profiling approach; preferred assay technology, supplier and outsourced fee-for-service providers; kinase profiling budgets and breakdown; interest in label free assays, multiplexed methods of kinase profiling and cell-based approaches for signaling pathway analysis of kinase inhibitors and features of a new kinase platform of greatest interest to respondents.

Table of contents

~Kinase Screening Profiling Trends 2006 (PDF)|749|~1736~2592~~
Ion Channel Trends 2006~
Published by HTStec Limited, July 2006

This market report summarizes the results of the third annual global Pharma/Biotech and Academic web-based benchmarking survey on ion channels. The objectives of this study were to better understand the impact of automated patch clamping (APC) and to gauge if its use will widen over the coming years, and to determine current interest and future requirements for ion channel screening using primary neural cells. The survey looked at various points including current use and experience of APC systems; areas where APC systems have been implemented; application areas where APC systems are expected to impact most; how respondents source human neuronal cells; what is preventing greater use and the timescale to use these cells; annual budgets for ion channel related cell lines and cell culture media and interest in accessing new neural cell products.~Published by HTStec Limited, July 2006

This market report summarizes the results of the third annual global Pharma/Biotech and Academic web-based benchmarking survey on ion channels. The objectives of this study were to better understand the impact of automated patch clamping (APC) and to gauge if its use will widen over the coming years, and to determine current interest and future requirements for ion channel screening using primary neural cells.

The survey looked at various points including current use and experience of APC systems; areas where APC systems have been implemented; application areas where APC systems are expected to impact most; how respondents source human neuronal cells; what is preventing greater use and the timescale to use these cells; annual budgets for ion channel related cell lines and cell culture media and interest in accessing new neural cell products.

Table of Contents~Ion Channel Trends 2006 Electronic Site License (PDF)|506|~1736~2490~~
Automated Low Volume Dispensing Trends 2006~
Published by HTStec, June 2006

This market report summarizes the results of a comprehensive global Pharma/Biotech and Academia web-based survey on automated low volume (nanoliter) dispensing. The survey looked at current and future use of low volume dispensing; plans and interest in the purchase of automated nL dispensing systems; applications for the use of nL dispensing; whether the systems should include detection capability, function stand-alone and whether additional functionality should be integrated with the dispenser to create a useful system; current and future total assay volume requirements; preferred method of integration and questions relating to acoustic droplet ejection (ADE).~Published by HTStec, June 2006

This market report summarizes the results of a comprehensive global Pharma/Biotech and Academia web-based survey on automated low volume (nanoliter) dispensing. The survey looked at current and future use of low volume dispensing; plans and interest in the purchase of automated nL dispensing systems; applications for the use of nL dispensing; whether the systems should include detection capability, function stand-alone and whether additional functionality should be integrated with the dispenser to create a useful system; current and future total assay volume requirements; preferred method of integration and questions relating to acoustic droplet ejection (ADE).

Table of contents

~Automated Low Volume Dispensing Trends 2006 (PDF)|742|~1736~2582~~
Label Free Detection Trends 2006~
Published by HTStec, April 2006

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on the current and future status of label free detection and its applications. The survey looked at various points including current or planned use of label free detection; new technology awareness; application and technical requirements. Among the questions covered in the survey was current ownership of label free detection systems, future plans to purchase new systems, basis for selection of new platforms This report will be of great value to those vendors developing or preparing to launch new label free detection technologies and to those existing vendors seeking to improve their current offerings or check alignment of the latest market needs.

~
Published by HTStec, April 2006

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on the current and future status of label free detection and its applications. The survey looked at various points including current or planned use of label free detection; new technology awareness; application and technical requirements. Among the questions covered in the survey was current ownership of label free detection systems, future plans to purchase new systems, basis for selection of new platforms This report will be of great value to those vendors developing or preparing to launch new label free detection technologies and to those existing vendors seeking to improve their current offerings or check alignment of the latest market needs.

Table of contents~Label Free Detection Trends 2006 (Eletronic site license PDF)|736|~1736~2573~~
Cell Culture Vessels Trends 2006~
Published by HTStec, February 2006

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on the current and future status of cell culture vessel trends. The survey covered areas including respondents’ responsibilities to purchase cell culture vessel manufacturers/distributors with preferred supplier status; relative ranking of these manufacturers/distributors on basis of annual budget spend, annual usage for both different types and specialized cell culture vessels; interest in new cell culture specific chemistries; unmet needs in cell culture vessels and specific coatings together with interest in Transwell permeable supports and other Transwell products.~
Published by HTStec, February 2006

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on the current and future status of cell culture vessel trends. The survey covered areas including respondents’ responsibilities to purchase cell culture vessel manufacturers/distributors with preferred supplier status; relative ranking of these manufacturers/distributors on basis of annual budget spend, annual usage for both different types and specialized cell culture vessels; interest in new cell culture specific chemistries; unmet needs in cell culture vessels and specific coatings together with interest in Transwell permeable supports and other Transwell products.

Table of contents

~Cell Culture Vessels Trends 2006|739|~1736~2675~~
High Throughput Screening 2005~
New Users, More Cell-Based Assays, and a Host of New Tools

Published by HighTech Business Decisions, October 2005

HTS for drug discovery is changing. To ensure success, HTS laboratories are helping to make certain their targets are validated, they are enlisting the help of collaborators from academic centers and institutes, increasing their use of high content screening and cell-based assays, improving the efficiencies of their primary screening, generating more focused libraries and focused screening, and are more involved with downstream processes to progress a compound to the clinic.~New Users, More Cell-Based Assays, and a Host of New Tools

Published by HighTech Business Decisions, October 2005

HTS for drug discovery is changing. To ensure success, HTS laboratories are helping to make certain their targets are validated, they are enlisting the help of collaborators from academic centers and institutes, increasing their use of high content screening and cell-based assays, improving the efficiencies of their primary screening, generating more focused libraries and focused screening, and are more involved with downstream processes to progress a compound to the clinic.

The report includes interviews with 54 HTS laboratory directors at academic centers and institutes to better understand their evolving role. It is worth noting that 104 identified drug candidates originated in their HTS laboratories and are currently being tested in humans, four are on the market.

Table of Contents ~High Throughput Screening 2005|237|~1736~1892~~
TR-FRET Based Assay Trends~
Published by HTStec, October 2005

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on TR-FRET based assays. The survey looked at various points including current use of TR-FRET based assays and other generic assay technologies; reasons for choosing TR-FRET based assays over alternative assays and vice versa; whether TR-FRET was a preferred assay technology and usage/spending today; current expertise in multiple assay technologies; TR-FRET reagent budget breakdown and opinion on reagent pricing per data point.~
Published by HTStec, October 2005

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on TR-FRET based assays. The survey looked at various points including current use of TR-FRET based assays and other generic assay technologies; reasons for choosing TR-FRET based assays over alternative assays and vice versa; whether TR-FRET was a preferred assay technology and usage/spending today; current expertise in multiple assay technologies; TR-FRET reagent budget breakdown and opinion on reagent pricing per data point.

Table of contents~TR-FRET Based Assay Trends (Eletronic Site License PDF)|733|~1736~2569~~
World Guide to Pharmaceutical Industry 2005~
Published by Bioseeker Group, August 2005

The 4th Edition of World Guide to Pharmaceutical Industry contains almost 3,000 profiles on drug developing companies from over 50 different nations. This edition has not only been updated but it has also been strengthened with a special inclusion and research on more than 200 drug delivery companies.

Companies are described by all their targeted therapeutic areas, short profile, contact information, web and email address. To reflect changes we have included a separate list of companies who have either filed for bankruptcy, undergone M&A etc.~ Published by Bioseeker Group, August 2005

The 4th Edition of World Guide to Pharmaceutical Industry contains almost 3,000 profiles on drug developing companies from over 50 different nations. This edition has not only been updated but it has also been strengthened with a special inclusion and research on more than 200 drug delivery companies.

Companies are described by all their targeted therapeutic areas, short profile, contact information, web and email address. To reflect changes we have included a separate list of companies who have either filed for bankruptcy, undergone M&A etc.

The World Guide to Pharmaceutical Industry is based on BioSeeker's proprietary CD-ROM technology which includes smart database structure, find and sort options, internet and email interactivity. All companies are provided with links, which connect you directly to the company webpage for further research. Companies can be further researched on from inside the application by linking search queries directly to search engines like Google and PubMed. Hence, World Guide to Pharmaceutical Industry brings important information closer to you from any one source. Found information on the CD-ROM may easily be shared with others over email or in print.

World Guide to Pharmaceutical Industry was created for professionals within the industry and for those with particular interest of the pharmaceutical industry, i.e. investors, trade organizations, and associated industry to that of pharmaceutical industry. Whether you are a CEO, business developer, in/out licensing officer, venture capitalist, consultant etc. you will find World Guide to Pharmaceutical Industry useful to locate M&A candidates, customers, collaboration partners, competitors etc.~World Guide to Pharmaceutical Industry 2005|1039|~1736~3155~~
Microplate Instrument Trends~
Published by HTStec, June 2005

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on microplate instrumentation trends carried out in May 2005. The main survey looked at the factors that currently limit productivity from a microplate instrumentation perspective; current and future use of microplate detection instruments and microplate readouts; liquid handling for bulk reagent dispensing and sample addition; difficulty in enabling liquid handling applications and reliability of dispensing; current and future use of microplate washers and washing applications; comparative vendor use and respondent ratings; use of different microplate formats and total assay volumes; data point metrics; and microplate instrument budgets and breakdown.~
Published by HTStec, June 2005

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on microplate instrumentation trends carried out in May 2005. The main survey looked at the factors that currently limit productivity from a microplate instrumentation perspective; current and future use of microplate detection instruments and microplate readouts; liquid handling for bulk reagent dispensing and sample addition; difficulty in enabling liquid handling applications and reliability of dispensing; current and future use of microplate washers and washing applications; comparative vendor use and respondent ratings; use of different microplate formats and total assay volumes; data point metrics; and microplate instrument budgets and breakdown.

Table of contents

~Microplate Instrument Trends (PDF)|753|~1736~2594~~
High Content Screening Trends~
Published by HTStec, March 2005

This market report summarizes the results of a comprehensive global Pharma/Biotech and University/Research Institute web-based survey on high content screening (HCS) trends carried out in February 2005.
~This market report summarizes the results of a comprehensive global Pharma/Biotech and University/Research Institute web-based survey on high content screening (HCS) trends carried out in February 2005.

Highlights of this Report:Table of Contents~High Content Screening Trends (Single user license)|1037|~1736~3153~~
Compound Management Trends~
Published by HTStec, December 2004

This market report summarizes the results of a global benchmarking web-based survey of Pharma and Biotech compound management groups. The objective of the study being to comprehensively document current practices, issues and future trends in compound management, with a particular focus on compound quality control and just-in-time compound delivery.~
Published by HTStec, December 2004

This market report summarizes the results of a global benchmarking web-based survey of Pharma and Biotech compound management groups. The objective of the study being to comprehensively document current practices, issues and future trends in compound management, with a particular focus on compound quality control and just-in-time compound delivery.

Highlights of this Report:

•The survey collected 70 responses (63 complete and 7 partially filled out) from 50 different Pharma and Biotech companies and 2 University/Research Institutes.
• Responses from were split geographically 44% North America and 56% Europe.
• Survey respondents were drawn from 32 Small-Medium Pharma/Biotechs, 31 Large Pharma, 2 Agrochemical Companies, 2 Contract Service Organisations, 2 University/Research Institutes and 1 Cosmetic Company.
• Respondents were either directly responsible for or directly involved in compound management within their company; or were closely involved in the preparation of assay ready plates from stocks provided by compound management. They represented 40 compound management groups; 20 screening groups; 3 corporate research management group; and 7 other groups.
• All data was presented and analyzed as the average response of All Survey Respondents. In addition, the data was fully reanalyzed after sub-division into the following 4 survey groups: 1) Large Pharma; 2) Small-Medium Pharma/Biotech; 3) Purchased Commercial Stores; and 4) Use of In House Alternatives.
• The mean size of a compound library today (2005) was 0.81 million compounds, this is expect to grow 1.42 million by 2008.
• Nearly one third of companies surveyed still use an ad hoc arrangement of lab freezers as the main component of their CM store.
• 60% of respondents had purchased a commercial CM store. REMP was the most popular commercial provider of the main component of their CM stores.
• Of the CM stores surveyed 68% represented a main (central) store, 27% a local site store and 5% a satellite lab store.
• Of the CM stores surveyed most used microplates and microtubes in part of the same facility;
• 89% of all liquid stocks today are in 100% DMSO (assumed starting concentration).
• The most common storage volume today is 0.1-0.5ml, this is also expected to be the case in 2008.

 Table of Contents

~Compound Management Trends (Eletronic Site License PDF)|771|~1736~2613~~
GPCR Assay Trends~
Published by HTStec, September 2004

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.~Untitled Document
Published by HTStec, September 2004

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.

Highlights of this Report:

• The survey collected 63 responses (52 complete and 11 partially filled out) from 48 different Pharma/Biotech companies.
• Responses were split geographically 43% North America and 57% Europe.
• Survey respondents were drawn from 27 Large Pharma, 33 Small Pharma/Biotechs, 1 Large Agro Company, Baby and Clinical Nutrition Company and 1 Pharma-Linked Research Organization.
• Survey respondents represented 27 primary screening (HTS) labs, 15 assay development labs, 12 secondary screening/hits-toleads (lead optimization) labs, 2 therapeutic area labs, 1 compound profiling lab and 6 other lab functions.
• Survey results were expressed as an industry average of all respondents. In addition, all results were fully reanalyzed after subdivision into the following survey groups: 1) by organization type - Large Pharma; 2) by organization type - Small Pharma/Biotech; 3) by geographic location - North America and 4) by geographic location – Europe.
• The mean number of primary GPCR screens undertaken in 2004 was estimated to be 7.1 screens per year with 489K wells (data points) per screen.
• Globally it was estimated that 1533 GPCR primary screens campaigns will be performed in 2004, 71% will be cell-based and 6% orphans.
• The Pharma market for GPCR primary screening reagents was estimated to be US$70Million in 2004, with an annual growth rate of 26%.
• The preferred approaches to GPCR profiling were to either to screen selected lead compounds in house against a GPCR panel or to outsource screening of selected lead compounds to a fee-for-service GPCR panel provider.
• The Pharma market for GPCR profiling was estimated in 2004 to be US$37.6Million and US$36.2Million for in house and outsourced profiling respectively.
• About 8X more data points were profiled against GPCRs in house versus outsourced in 2004.
• The mean budget allocated per lab for GPCR profiling in 2004 was estimated to be US$175K in house versus US$168K for outsourced profiling.
• The mean price per data point for GPCR profiling was estimated to be US$4.30 in house versus US$35.42 for outsourced.
• The mean number of FTEs supporting in house GPCR screening and profiling was 5.4 and 2.8 FTEs/lab respectively.

Table of Contents

~GPCR Assay Trends (PDF)|775|~1736~2619~~
Secondary Screening~
Published by Select Biosciences, October 2003

~Untitled DocumentView Sample Pages
View sample company profile

The market for in vitro toxicology testing is approximately $200 million and expected to grow to more than $300 million by 2005. 90% of compounds fail in drug development because of four reasons. 41% of those fail because of poor ADME; 31% because of insufficient efficacy; 22% because of toxicity; and only 6% because of market and/or commercialization complications. The earlier in the development process that an inadequate compound can be removed, the less time and money wasted, usually on the order of five to ten years and hundreds of millions of dollars.

The triage process thus represents a large opportunity with significant unmet needs, and new technologies are defining and expanding this market. Triage starts immediately after primary high-throughput screening, and the market opportunity for re-screening of hits is approximately $190 million worldwide and expected to grow to more than $250 million by 2005. The market opportunities for toxicology and ADME currently total approximately $3 billion, most of which is spent on animal studies. The market for in vitro toxicology testing, the segment within secondary screening, is approximately $200 million and expected to grow more than $300 million by 2005. The market for in vitro ADME testing represents a conversation opportunity and is forecasted to remain relatively stable.

Contents

View full table of contents



Executive Summary
Secondary Screening Space
Market Analysis
Competitive Landscape

~Secondary Screening%3A Chapter 1%3A Excutive Summary (PDF)|78|Secondary Screening%3A Chapter 2%3A SEcondary Screening Space (PDF)|79|Secondary Screening%3A Chapter 3%3A Market Analysis (PDF)|80|Secondary Screening%3A Chapter 4%3A Competitive Landscape (PDF)|81|Secondary Screening%3A Full Report - PDF Site License + 1 Print Copy|82|Secondary Screening%3A Full Report - Single User Print Version|83|~1736~2489~~
Menu Page | Toolbar Page |
Frameset Page | Index Page | Table of Contents
EROL - Electronic Retail Online E-commerce shopping cart software